Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.4 million.

  • Phathom Pharmaceuticals' Net Cash Flow fell 12466.29% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.5 million, marking a year-over-year decrease of 26488.74%. This contributed to the annual value of -$84.1 million for FY2024, which is 13684.04% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Net Cash Flow of -$14.4 million as of Q3 2025, which was down 12466.29% from -$62.7 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Net Cash Flow ranged from a high of $167.7 million in Q4 2023 and a low of -$84.9 million during Q1 2025
  • For the 4-year period, Phathom Pharmaceuticals' Net Cash Flow averaged around -$9.4 million, with its median value being -$32.8 million (2023).
  • The largest annual percentage gain for Phathom Pharmaceuticals' Net Cash Flow in the last 5 years was 55630.35% (2023), contrasted with its biggest fall of 21116.16% (2023).
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Net Cash Flow stood at -$41.5 million in 2022, then soared by 504.61% to $167.7 million in 2023, then plummeted by 122.31% to -$37.4 million in 2024, then soared by 61.48% to -$14.4 million in 2025.
  • Its Net Cash Flow stands at -$14.4 million for Q3 2025, versus -$62.7 million for Q2 2025 and -$84.9 million for Q1 2025.